Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: Subgroup analysis of a double-blind randomized controlled trial.
The article presents a study which identifies the impact of raloxifene on the vascular biomarkers and disease activity in 62 patients who are suffering with systemic lupus erythematosus (SLE). The study uses the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) for the evaluation of the disease activity. Results show that the lumbar spine bone mineral density (BMD) is improved by raloxifene in SLE patients.